Halozyme navigates CMS pricing risks impacting 2028+ revenues, yet strong royalties, FY25 guidance, and margins support ...

Halozyme Therapeutics HALO has outperformed the market over the past 15 years by 2.54% on an annualized basis producing an ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Merck secures U.S. Patent Office backing in its legal battle with Halozyme over Keytruda's injectable version. Read more here ...

Sterling, BJ's, Molina, and Halozyme stand tall with robust earnings growth and high interest coverage in June picks.

Merck, as it prepares a new version of its cancer blockbuster Keytruda, gets a boost in its patent dispute with Halozyme ...

Meridian Funds, managed by ArrowMark Partners, released its “Meridian Growth Fund” first quarter 2025 investor letter.

Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here.

Halozyme Therapeutics HALO has outperformed the market over the past 5 years by 4.46% on an annualized basis producing an average annual return of 17.65%. Currently, Halozyme Therapeutics has a market ...

Replays of the audio webcasts will be available for 90 days following the conference. Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and ...

In the late 2010s, Novo Nordisk shelved a weekly obesity treatment that targeted three hormones at once, though it caused ...